Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts.

Li J, Cona MM, Chen F, Feng Y, Zhou L, Zhang G, Nuyts J, de Witte P, Zhang J, Yu J, Oyen R, Verbruggen A, Ni Y.

Theranostics. 2013;3(2):127-37. doi: 10.7150/thno.5790. Epub 2013 Feb 13.

2.

Combretastatin A4 phosphate: a novel vascular disrupting agent.

Nagaiah G, Remick SC.

Future Oncol. 2010 Aug;6(8):1219-28. doi: 10.2217/fon.10.90. Review.

PMID:
20799867
3.

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

Siemann DW, Chaplin DJ, Walicke PA.

Expert Opin Investig Drugs. 2009 Feb;18(2):189-97. doi: 10.1517/13543780802691068 . Review.

4.

Combretastatin A4 phosphate.

West CM, Price P.

Anticancer Drugs. 2004 Mar;15(3):179-87. Review.

PMID:
15014350
5.

An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.

Cona MM, de Witte P, Verbruggen A, Ni Y.

World J Methodol. 2013 Dec 26;3(4):45-64. doi: 10.5662/wjm.v3.i4.45. eCollection 2013 Dec 26. Review.

6.

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions.

Liang W, Ni Y, Chen F.

Oncotarget. 2016 Mar 29;7(13):15444-59. doi: 10.18632/oncotarget.6999. Review.

Supplemental Content

Support Center